Abstract
The sum of target lesions is routinely used to evaluate patient objective responses to treatment in the RECIST criteria, but it neglects the response heterogeneity across metastases. This study argues that the spatiotemporal response heterogeneity across metastases informs drug efficacy and patient survival. We analyzed the longitudinal data of 11,404 metastatic lesions in 2,802 colorectal cancer patients and examined their response heterogeneity. The response dynamics of metastatic lesions varied broadly across anatomical locations and therapies. High inter-lesion heterogeneity is associated with worse survival (p < 0.001), while targeted therapies (bevacizumab or panitumumab) reduced the inter-lesion heterogeneity (p < 0.05) and elicited more favorable effects on liver lesions (p < 0.001) than chemotherapy alone. The responses of liver lesions predicted patient survival more significantly than the lesions in the lungs and lymph nodes. Altogether, the high spatiotemporal heterogeneity across metastases should be integrated into current methods for treatment evaluation and patient prognosis.
Significance The spatiotemporal heterogeneity across metastases in response to first-line therapies in colorectal cancer is informative for drug efficacy and patient survival, particularly in targeted therapy. Our findings provide evidence to support the inclusion of individual lesion response in the RECIST to improve the assessment of drug efficacy and patient survival.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
there is a retrospective analysis of several trials, a table of these trials' ID has been provided in the supplementary material
Funding Statement
Supported by NIH NIGMS GM119661
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a retrospective analysis of several clinical trials, each of which has been registered with the approved IRB documents.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: The authors declare that there is no conflict of interest regarding the publication of this article
Financial support: Y. Cao and J. Zhou were funded by National Institute of Health (GM119661).
Data Availability
All data has made available in the supplementary materials
Abbreviations
- RECIST
- Response Evaluation Criteria in Solid Tumors
- LN
- lymph nodes
- GI
- gastrointestinal
- CRC/mCRC
- colorectal cancer/metastatic colorectal cancer
- PFS
- progression-free survival
- OS
- overall survival
- ILH
- inter-lesion heterogeneity
- Beva
- bevacizumab
- Pani
- panitumumab
- Chemo
- chemotherapy
- FOLFOX
- folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (Eloxatin)
- FOLFIRI
- folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (Camptosar)
- MAPK
- mitogen-activated protein kinase
- EGFR
- epidermal growth factor receptor
- VEGF
- vascular endothelial growth factor
- BSA
- body surface area
- LDH
- lactate dehydrogenase
- HR
- hazard ratio
